Clinical Trials Directory

Trials / Completed

CompletedNCT00230568

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

A 12-Week, Multicenter, Open-Label Study to Evaluate the Effectiveness and Safety of Donepezil Hydrochloride (Aricept) in Hispanic Patients With Mild to Moderate Alzheimer's Disease

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
100 (actual)
Sponsor
Eisai Inc. · Industry
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer's Disease (AD) in the U.S.

Conditions

Interventions

TypeNameDescription
DRUGAricept

Timeline

Start date
2005-12-01
Primary completion
2007-04-01
Completion
2007-12-01
First posted
2005-10-03
Last updated
2011-04-01

Locations

35 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00230568. Inclusion in this directory is not an endorsement.

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD) (NCT00230568) · Clinical Trials Directory